Liver Therapy Collaboration Cellaïon develops Hepastem for liver repair, offering a compelling platform for licensing, co-development, or strategic partnerships with pharma to advance liver failure programs from preclinical through Phase IIB trials.

Funding Momentum Recent financing activity and a sizable 2022 fundraising indicate investor readiness to support rapid clinical advancement, making partnerships with investors attractive for co-development, strategic alliances, or milestone-driven deals with larger biopharma.

European Growth Based in Belgium with European fundraising history, Cellaïon is well positioned to engage European CROs, regulatory experts, and EU funding programs, enabling efficient trial execution and market access collaborations across Europe.

Lean Team Advantage A lean organization (11-50 employees) can benefit from outsourced development services, contract manufacturing support, IP licensing, or co-development arrangements to accelerate timelines while preserving lean internal operations.

Phase IIB Pathway Funding tied to a Phase IIB program in Acute on Chronic Liver Failure highlights a clear clinical development pathway and potential for commercial partnerships post-trial, including licensing or acquisition talks with mid- to late-stage biopharma.